Pipeline Sanofi drops two more programmes in R&D clear-out PharmaphorumShortly after terminating one late-stage R D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.Read full story pharminent July 30, 2026 (Last updated: August 3, 2026) Pharmaphorum Shortly after terminating one late-stage R D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped. Read full story Post navigation Previous: GSK Cambridge Move Signals Shift in Drug Scale-Up StrategyNext: Amgen’s Repatha Wins Positive CHMP Opinion for Preventing First Heart Attacks and Strokes Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
